Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
365.81
-5.43 (-1.46%)
At close: Jul 10, 2026, 4:00 PM EDT
357.03
-8.78 (-2.40%)
After-hours: Jul 10, 2026, 6:41 PM EDT
Krystal Biotech Employees
Krystal Biotech had 295 employees as of December 31, 2025. The number of employees increased by 20 or 7.27% compared to the previous year.
Employees
295
Change (1Y)
20
Growth (1Y)
7.27%
Revenue / Employee
$1,414,590
Profits / Employee
$762,814
Market Cap
10.78B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 295 | 20 | 7.27% | 295 | 0 |
| Dec 31, 2024 | 275 | 46 | 20.09% | 275 | 0 |
| Dec 31, 2023 | 229 | 19 | 9.05% | 229 | 0 |
| Dec 31, 2022 | 210 | 91 | 76.47% | 210 | 0 |
| Dec 31, 2021 | 119 | 44 | 58.67% | 119 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
| Summit Therapeutics | 265 |
| Apogee Therapeutics | 261 |
KRYS News
- 23 days ago - Krystal Biotech price target raised to $403 from $306 at TD Cowen - TheFly
- 25 days ago - Krystal Biotech price target raised to $361 from $310 at H.C. Wainwright - TheFly
- 7 weeks ago - Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call - GlobeNewsWire
- 7 weeks ago - Krystal Biotech Slides: Corporate presentation - Filings
- 7 weeks ago - Krystal Biotech announces UK MHRA approval of Vyjuvek - TheFly
- 7 weeks ago - Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 2 months ago - Krystal Biotech Transcript: AGM 2026 - Transcripts
- 2 months ago - U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa - TheFly